Table 1.
Baseline characteristics of patients with MPA and GPA (N = 132)
| Variables | Values |
|---|---|
| Demographic data | |
| Age at diagnosis (year old) | 57.2 ± 14.7 |
| Male gender (N, (%)) | 40 (30.3) |
| AAV variants (N, (%)) | |
| MPA | 91 (68.9) |
| GPA | 41 (31.1) |
| ANCA positivity (N, (%)) | 112 (84.8) |
| Activity and prognostic factor at diagnosis | |
| BVAS | 13.1 ± 7.2 |
| FFS (2009) | 1.4 ± 1.0 |
| FFS (2009) ≥ 2 (N, (%)) | 57 (43.2) |
| Laboratory results at diagnosis | |
| White blood cell (/mm3) | 9538.3 ± 3940.5 |
| Haemoglobin (g/dL) | 12.0 ± 1.2 |
| Platelet × 103 (/mm3) | 331.8 ± 144.7 |
| Prothrombin time (INR) | 1.0 ± 0.1 |
| Fasting glucose (mg/dL) | 116.8 ± 44.6 |
| Blood urea nitrogen (mg/dL) | 28.1 ± 25.3 |
| Creatinine (mg/dL) | 1.9 ± 2.1 |
| Protein (g/dL) | 6.7 ± 0.9 |
| Serum albumin (g/dL) | 3.5 ± 0.8 |
| Alkaline phosphatase (IU/L) | 93.7 ± 94.3 |
| Aspartate aminotransferase (IU/L) | 23.2 ± 26.5 |
| Alanine aminotransferase (IU/L) | 23.4 ± 39.3 |
| Total bilirubin (mg/dL) | 0.7 ± 1.6 |
| Total cholesterol (mg/dL) | 171.4 ± 50.4 |
| Acute reactants at diagnosis | |
| Erythrocyte sedimentation rate (mm/hr) | 62.8 ± 38.0 |
| C-reactive protein (mg/L) | 44.0 ± 56.8 |
| Liver fibrosis index at diagnosis | |
| FIB-4 | 1.1 ± 0.9 |
| FIB-4 ≥ 1.45 (N, (%)) | 27 (20.5) |
| Comorbidities except items of BVAS or FFS (2009) at diagnosisa (N, (%)) | |
| DM | 26 (19.7) |
| HTN | 61 (46.2) |
| Follow-up duration (months) | 52.4 ± 52.2 |
| Death (N, (%)) | 15 (11.4%) |
Values are expressed as a mean ± standard deviation and number (N) (%)
a interstitial lung disease, diffuse alveolar haemorrhage, gastrointestinal bleeding, cardiovascular diseases, chronic kidney disease ≥ stage 3 and cerebrovascular accident and so on
AAV ANCA-associated vasculitis, ANCA antineutrophil cytoplasmic antibody, MPA microscopic polyangiitis, GPA granulomatosis with polyangiitis, BVAS Birmingham vasculitis activity score, FFS five factor score, FIB-4 fibrosis-4, DM diabetes mellitus, HTN hypertension